Liver function abnormality during dacomitinib/Dozerun treatment, should it be discontinued or dose reduced?

During treatment with dacomitinib/Dacomitinib, some patients may develop abnormal liver function. This is mainly related to the fact that the liver is an important organ for drug metabolism and excretion. When drugs inhibit or affect liver cell metabolism, liver function indicators such as transaminases may increase. For clinicians, reasonable response to liver function abnormalities is an important step in ensuring the safety and efficacy of treatment.

Generally speaking, the management strategy for liver function abnormalities needs to be determined based on the degree of abnormality and the patient's overall condition. For mild liver function elevation (usually when transaminase slightly exceeds the upper limit of normal), the original dose can be maintained while continuing observation, and liver function monitoring should be strengthened to ensure that changes in indicators are controllable. During this period, patients should avoid drinking alcohol and taking drugs that may increase the burden on the liver, and maintain a healthy diet to reduce pressure on the liver.

When liver function indicators reach moderate or severe abnormalities, it is usually clinically recommended to suspend the medication and consider restarting treatment after the liver function returns to a safe range. At the same time, the dose of dacomitinib can be appropriately reduced to reduce the burden on the liver. Some guidelines also recommend regular follow-up of liver function after resumption of medication and dose adjustment according to changes in indicators, thereby ensuring efficacy while reducing the risk of adverse reactions.

In addition, abnormal liver function may be related to individual metabolic differences, concomitant medication, or underlying liver disease. Therefore, during the treatment process, doctors will comprehensively evaluate the patient's medical history, medication history, and liver function change trends to formulate an individualized plan. Scientific monitoring and reasonable dose adjustment can maximize the therapeutic effect of dacomitinib while reducing the risk of severe hepatotoxicity.

In general, liver function abnormalities that occur during dacomitinib treatment are managed depending on the degree of abnormality. Mild abnormalities can continue to be observed and closely monitored. For moderate and above abnormalities, the drug usually needs to be discontinued and dosage reduction can be considered after liver function recovers.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro